Objective.A phase Ⅱ study was conducted to determ inethe efficacy of single agent flavopiridol therapy in patients with recurrent or persistent endometrial adenocarcinoma refractory to established treatments. Methods...Objective.A phase Ⅱ study was conducted to determ inethe efficacy of single agent flavopiridol therapy in patients with recurrent or persistent endometrial adenocarcinoma refractory to established treatments. Methods. Eligible patients with measurable disease who failed primary therapy including one cytotoxic regim en were eligible for the trial.They were treated with single agentflavopiridol (50mg/m2/day,Ⅳ bolus days 1,2,3).Treatm entwas repeatedevery 21days with dose adjustm ents made for toxicity.Patients were treated untilprogression ofdisease oradverseside effects precluded further therapy.Results.A totalof26patientswere enrolled in the study ofwhom ,23patientswere eligible.There were no objective responses.Fivepatients had stable disease (22%),15 (65%)had in-creasing disease,and response could notbe assessed in 3(13%).The mostfrequentside effects included anemia,neutropenia,and diarrhea,allofwhich appeared manage-able.Conclusion.Flavopiridol as a single agent in theabove dosing schedule appears to have minim alactivity assecond-line chem otherapy ofendom etrialadenocarcinoma.展开更多
文摘Objective.A phase Ⅱ study was conducted to determ inethe efficacy of single agent flavopiridol therapy in patients with recurrent or persistent endometrial adenocarcinoma refractory to established treatments. Methods. Eligible patients with measurable disease who failed primary therapy including one cytotoxic regim en were eligible for the trial.They were treated with single agentflavopiridol (50mg/m2/day,Ⅳ bolus days 1,2,3).Treatm entwas repeatedevery 21days with dose adjustm ents made for toxicity.Patients were treated untilprogression ofdisease oradverseside effects precluded further therapy.Results.A totalof26patientswere enrolled in the study ofwhom ,23patientswere eligible.There were no objective responses.Fivepatients had stable disease (22%),15 (65%)had in-creasing disease,and response could notbe assessed in 3(13%).The mostfrequentside effects included anemia,neutropenia,and diarrhea,allofwhich appeared manage-able.Conclusion.Flavopiridol as a single agent in theabove dosing schedule appears to have minim alactivity assecond-line chem otherapy ofendom etrialadenocarcinoma.